Opiranserin (INN ; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC50 = 0.86 μM), purine P2X3 receptor antagonist (IC50 = 0.87 μM), and serotonin 5-HT2A receptor antagonist (IC50 = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain.[1][2][3][4] As of April 2017, it is in phase II clinical trials for this indication.[3] The INN of the drug was issued in 2017.[2]
Clinical data | |
---|---|
Other names | VVZ-149; VVZ-000149 |
Routes of administration | Intravenous |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
Chemical and physical data | |
Formula | C21H34N2O5 |
Molar mass | 394.512 g·mol−1 |
3D model (JSmol) |
|
| |
|